KalVista Pharmaceuticals Ltd, a new UK ophthalmology company, is set to receive up to $2.2 million in milestone-based support from the Juvenile Diabetes Research Foundation (JDRF) to finance a pre-clinical drug to treat diabetic macula edema. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News